SAVR may be even safer for low-risk patients than previously believed, according to new research published in the Journal of Thoracic and Cardiovascular Surgery. What does this tell us about patient care going forward?

Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope. 

The 88-year-old patient was originally not seen as a viable candidate for TAVR or surgery.

The cardiologist's bond has been set at $5 million. He will appear in court next on June 22 for a preliminary hearing.

Multiple medical devices used during cardiopulmonary bypass and extracorporeal membrane oxygenation procedures have been voluntarily recalled due to issues with their packaging.

This latest acquisition continues what has been a busy year for Cardiovascular Associates of America. 

Bullying and other inappropriate workplace behaviors have been linked to an increased risk of errors and worse patient outcomes. 

Samuel Jones, MD, examines the large reimbursement reductions in cardiac ablations and what the impact might be on access to care in EP labs.

The goal is to inform users on how to best utilize AI tools while also practicing caution, as many are still in their early stages of deployment and can pose risks. 

CFO Mark Stolper recently spoke about the imaging group's artificial intelligence strategy at the Jefferies Healthcare Conference in New York.